Take­da shares pos­i­tive Phase II­Ib da­ta; NIA grant for Phase II study on new oral Alzheimer's treat­ment

→ Take­da says its VAR­SI­TY, Phase II­Ib study “demon­strat­ed that the gut-se­lec­tive bi­o­log­ic vedolizum­ab (En­tyvio) was su­pe­ri­or to the an­ti-tu­mor necro­sis fac­tor-al­pha (an­ti-TN­Fα) bi­o­log­ic adal­i­mum­ab (Hu­mi­ra) in achiev­ing clin­i­cal re­mis­sion at week 52 in pa­tients with mod­er­ate­ly to se­vere­ly ac­tive ul­cer­a­tive col­i­tis. New ex­plorato­ry da­ta showed that a greater pro­por­tion of pa­tients re­ceiv­ing vedolizum­ab in­tra­venous (IV) achieved clin­i­cal re­sponse at week 14 com­pared to those treat­ed with adal­i­mum­ab sub­cu­ta­neous (SC), 67.1% vs. 45.9% re­spec­tive­ly. A sep­a­ra­tion be­tween the treat­ment groups was seen as ear­ly as week 6, fa­vor­ing vedolizum­ab.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER